Clinical Trials Logo

Nilotinib clinical trials

View clinical trials related to Nilotinib.

Filter by:
  • None
  • Page 1

NCT ID: NCT03942094 Recruiting - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Start date: June 1, 2019
Phase: Phase 3
Study type: Interventional

This is a phase IIIb, multi-centre, single-arm, open-label, prospective study investigating the efficacy and safety of nilotinib as the first-line treatment for the adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in China. Nilotinib 300 mg BID will be provided in this study. The assessment for the primary efficacy endpoint will be performed at 18 months and the rate of patients obtaining MR4.5 will be measured at this time point. Secondary endpoints include the complete hematologic response(CHR) and the rates of major molecular reactions (MMR) by 3, 6, 9,12,18 and 24 months; event free survival (EFS); overall survival (OS).

NCT ID: NCT01206088 Completed - CML Clinical Trials

Tasigna in Glivec-resistant or Intolerant Patients in CML

Start date: February 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete cytogenetic response rate(CCyR) at 12 months after nilotinib administration.